Drug Profile
MAX 40070
Alternative Names: MAX-3; MAX-40070Latest Information Update: 11 Apr 2023
Price :
$50
*
At a glance
- Originator Maxinovel Pharmaceuticals
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase inhibitors; TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alopecia areata
- Preclinical Atopic dermatitis; Psoriasis
Most Recent Events
- 11 Apr 2023 MAX 40070 is still in preclinical development for Alopecia areata in China (Topical) (Maxinovel Pharmaceuticals pipeline, April 2023)
- 11 Apr 2023 Maxinovel plans phase I trial in Aloepecia areata, Psoriasis and Atopic dermatitis in 2023 (Maxinovel Pharmaceuticals pipeline, April 2023)
- 11 Apr 2023 Maxinovel plans phase II trial in Aloepecia areata, Psoriasis and Atopic dermatitis in 2024 (Maxinovel Pharmaceuticals pipeline, April 2023)